Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis-A Retrospective Database Study.
Philipp SewerinKathrin BorchertDominic MeiseMatthias SchneiderJörg MahlichPublished in: Rheumatology and therapy (2021)
The one-year persistence rate for bDMARDs in German PsA patients is modest, although the persistence rate depends on the bDMARD considered.